SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Bill Wexler's Profits of DOOM
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bill Wexler who wrote (2)2/20/1998 9:44:00 AM
From: Jim Roof  Read Replies (1) of 4634
 
Hello Bill,

Nice to see you have cordoned off an area where you can do what you do best.

Just a word to others here. A few things you should know about Bill.

1. He takes every negative as if it were the Gospel itself regardless of the source.

2. Since every negative heard is the Gospel to Bill any data or hard evidence, or anecdotal evidence to the contrary is because company 'abc' or 'xyz' is running a scam. This word will appear often here in Bill's posts.

3. Any stock that moves contrary to his predetermined ideas is somehow 'manipulated'. Bill is right. His rumors are right. His flawed interpretation of data is right. Everything else is wrong. Every historical event in the markets that go contrary to his designs are the result of sinister Anti-Wexler forces.

Now back to you, Bill.

You still have yet to explain why the Biotime insiders continue to BUY and have not yet sold ONE share. They have the deepest and broadest knowledge of their business.

You also did not respond with any data to support your claim that Hextend is not superior to Hespan despite the data that came out of the Phase III trials (which, BTW, were not even designed to show superiority - just equivalency). Of the 10 serious complications that were determined to be related to the volume expanders (this determination made before un-blinding took place) only 2 were in the Hextend group while 8 were in the Hespan/generic group. Heart rate after surgery was consistantly lower with Hextend. Hextend patients received less whole blood and less platelets. Hextend patients bled less after and during surgery. Hextend patients maintained much better calcium levels. Hextend patients stayed an average of one day less in the hospital. I know that statistical significance was not reached in some of these areas BUT the fact is that across the board there were NO negatives and ALL positives in these gray areas. I would suspect that chance alone could not account for such a wide sweeping positive outcome from the trials.

Now, back to all here-

Sit back and read Bill's response to my questions and the data and see if this is the kind of guy you would trust with your money.

Jim
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News